Primary Hyperaldosteronism
13
2
3
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
Tissue K+ in Primary Hyperaldosteronism
HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)
Dynamic Hormone Diagnostics in Endocrine Disease
Radiofrequency Endoscopic Ablation With Ultrasound Guidance: a Non-surgical Treatment for Aldosterone-producing Adenomas
A Prospective Cohort Study for Patients With Adrenal Diseases
11C-Metomidate PET Versus Adrenal Vein Sampling in Primary Aldosteronism
Primary Hyperaldosteronism and Ischemia-reperfusion Injury
Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism
Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment
Intraoperative Analysis of Cortisol During Adrenal Vein Sampling
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism